Literature DB >> 10849091

Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.

R Hildenbrand1, M Leitz, V Magdolen, T Luther, S Albrecht, H Graeff, H J Stutte, U Bleyl, M Schmitt.   

Abstract

AIMS: Ductal carcinoma in situ (DCIS) is a pre-invasive form of mammary carcinoma with no microscopic evidence of cancer cell invasion through the basement membrane. However, for initiation of invasion, tumour cells have to acquire and focus proteolytic activity on to the cell surface in order to infiltrate the surrounding extracellular matrix. The receptor (uPA-R or CD87) for the serine protease urokinase-type plasminogen activator (uPA) plays a central role in invasion and metastasis. This study was performed to determine and localize m-RNA and protein of uPA-R in ductal carcinoma in situ of the breast. METHODS AND
RESULTS: We analysed uPA-R mRNA and protein expression by in-situ hybridization and immunohistochemistry, respectively, in 50 formalin-fixed, paraffin-embedded specimens of DCIS. Three different antibodies were used to stain cell-associated uPA-R; chicken polyclonal antibody (pAb) HU277 and monoclonal antibodies (mAb) IID7 and 3936. In all cases, myoepithelial and stromal cells reacted with either antibody. Especially, reaction of macrophage-like cells with mAb 3936 resulted in a well-marked and bright staining. Applying mAb IID7, in 46 of the 50 breast specimens tumour cells showed a positive immunoreaction. Likewise pAb HU277 stained tumour cells in 40 of the 50 cases, whereas mAb 3936 reacted with only 24 of the 50 tissue sections. Endothelial cells were marked by both mAb IID7 and pAb HU277 (46/50 and 35/50, respectively); mAb 3936 did not label at all. All of the cell types stained by mAb IID7 and pAb HU277 also displayed reactivity with uPA-R mRNA-specific antisense oligonucleotides in in-situ hybridization.
CONCLUSIONS: Our results reveal the presence of the tumour invasion-related receptor for the protease uPA not only in invasive ductal breast carcinoma but also in different types of DCIS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10849091     DOI: 10.1046/j.1365-2559.2000.00899.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

1.  Expression of proteinases and inhibitors in human breast cancer progression and survival.

Authors:  E A Baker; T J Stephenson; M W R Reed; N J Brown
Journal:  Mol Pathol       Date:  2002-10

2.  Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group.

Authors:  Ralf Hildenbrand; Marco Niedergethmann; Alexander Marx; Djeda Belharazem; Heike Allgayer; Christiane Schleger; Philipp Ströbel
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

3.  Seroprevalence of Helicobacter pylori/CagA Antibodies in Guatemalan Gastric Cancer Patients: Association of Seropositivity with Increased Plasma Levels of Pepsinogens but not Soluble Urokinase Plasminogen Activator Receptor.

Authors:  Rafael Fernandez-Botran; Irmgardt Alicia Wellmann; Clas Une; Ericka Méndez-Chacón; Elisa Hernández de Rodas; Bikash Bhandari; Carmen I Villagrán de Tercero
Journal:  Am J Trop Med Hyg       Date:  2020-04-16       Impact factor: 2.345

Review 4.  Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.

Authors:  Morten Persson; Andreas Kjaer
Journal:  Clin Physiol Funct Imaging       Date:  2013-04-03       Impact factor: 2.273

5.  Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.

Authors:  R Hildenbrand; N Arens
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.